HIM
RYTM icon

Hillsdale Investment Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Hillsdale Investment Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.89M Buy
44,000
+3,700
+9% +$335K 0.11% 238
2026
Q1 		$3.5M Sell
40,300
-2,000
-5% -$194K 0.1% 255
2025
Q4 		$4.53M Sell
42,300
-300
-0.7% -$31.8K 0.13% 223
2025
Q3 		$4.3M Buy
+42,600
New +$3.95M 0.13% 225
2018
Q3 		– Sell
-2,400
Closed -$75K – 540
2018
Q2 		$75K Buy
+2,400
New +$65.6K 0.01% 304

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Hillsdale Investment Management's RYTM Position: Q2 2026 in Review

Hillsdale Investment Management increased its Rhythm Pharmaceuticals (RYTM) stake by 9.2% in Q2 2026, buying an estimated $335K and bringing the position to 44,000 shares worth $4.89M. The position accounts for 0.11% of the portfolio, ranked #238.

Hillsdale Investment Management first reported a position in RYTM in Q2 2018 and has held it in 5 quarters since. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Hillsdale Investment Management held 44,000 shares of Rhythm Pharmaceuticals worth $4.89M as of Q2 2026.
  • Hillsdale Investment Management bought 3,700 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $335K.
  • Rhythm Pharmaceuticals made up 0.11% of Hillsdale Investment Management's portfolio in Q2 2026, its #238 holding.
  • Hillsdale Investment Management first reported a position in Rhythm Pharmaceuticals in Q2 2018 and has held it in 5 quarters since.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Hillsdale Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.